Chris Groppa has been appointed chief marketing officer and director of reimbursement for TranS1.
Groppa will oversee the company’s marketing activities, and will continue to oversee its US insurance reimbursement strategy.
He brings over a decade of digital marketing, communications and product development experience to the TranS1 team. His prior experience includes product development work with Blue Cross Blue Shield Association, brand marketing for IBM, as well as extensive marketing communications agency experience. He received his Bachelor’s Degree from the University of Wisconsin-Madison and a Master of Business Administration from the University of Notre Dame.
“AxiaLIF can truly change people’s lives for the better, and the opportunity to work on such a special product is very exciting,” said Groppa. “I’m also thrilled to be located in the heart of Denver, one of the most dynamic health-tech markets in the country, and the ideal place to build our business.”
TranS1’s flagship product, AxiaLIF, offers surgeons and patients a minimally invasive alternative for fusion at the L5-S1 joint. Peer-reviewed medical studies report that AxiaLIF patients experience reduced pain and blood loss, shorter hospital stays and faster recovery times compared to traditional approaches to L5-S1 fusion.
“Chris brings a fresh perspective to TranS1. His extensive marketing experience and work in the insurance industry is a huge asset to our company. We look forward to supporting him as he does great things at TranS1,” says Jeff Schell, TranS1’s president and chief executive officer.
